Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2003
08/14/2003US20030153541 Liver X receptor modulator comprising an oxysterol, lipid regulating HMG-CoA reductase inhibitor, fibric acid derivative, niacin, bile-acid sequestrant, probucol, raloxifene, unsaturated omega-3 fatty acid
08/14/2003US20030153540 For improving health in a woman having elevated sex hormone binding globulin levels, or who is receiving oral estrogen supplementation
08/14/2003US20030153539 Use of estramustine phosphate or a metabolite thereof in preparation of anticarcinogenic agent
08/14/2003US20030153538 Comprises as effective component a compound selected from maslinic acid, erythrodiol, uvaol, betulinic acid, betulin and physiologically acceptable salts thereof or derivatives thereof
08/14/2003US20030153537 Reducing tetracycline resistance in living cells
08/14/2003US20030153536 Compounds and methods of treating transplant rejection
08/14/2003US20030153535 For therapeutic, prophylactic, diagnostic and screening purposes; cells present a reference amount of oxidative damage or senescence
08/14/2003US20030153534 Phosphonate nucleotide compound
08/14/2003US20030153533 Novel phospholipid derivatives
08/14/2003US20030153532 Immunomodulatory compounds and methods of use thereof
08/14/2003US20030153531 Modified polysaccharides exhibiting altered biological recognition
08/14/2003US20030153530 Solubility enhancing component other than a cyclodextrin, particularly a polyanionic component, an oxy-chloro component to aid in preserving the composition, liquid carrier
08/14/2003US20030153529 Dextrin containing compositions for prevention of adhesions
08/14/2003US20030153528 Hemostatic bone wax composition
08/14/2003US20030153526 Compositions contain antisense oligonucleotides that hybridize to Grb2 and Crkl nucleic acids, gene products of which are known to interact with tumorigenic protein bcr-abl
08/14/2003US20030153525 Identifies differential expression of 1465, 1587, 2146, 2207, 32838, 336 OR 52908 genes in tissues relating to pain sensation relative to their expression in normal or non-painful disease states
08/14/2003US20030153524 Including extracellular matrix production and/or deposition, neovascularization, inflammation, cell proliferation, cell migration, associated with connective tissue growth factor by administering agent that decreases expression of the factor
08/14/2003US20030153523 Screening library of test compounds, each of which is attached to a solid support, with a dye-labeled RNA molecule to form a dye-labeled target RNA:support-attached test compound complex
08/14/2003US20030153519 Drug delivering a nucleic acid and an RNase inhibitor to a target cell of a vascularized multi-cellular organism; RNA interference
08/14/2003US20030153518 Activation and inhibition of the immune system
08/14/2003US20030153517 Therapeutic use of ganglioside GM1 in the treatment of spinal cord injury
08/14/2003US20030153516 Methods and materials for treating and preventing inflammation of mucosal tissue
08/14/2003US20030153515 Administering icariin for sexual disorders
08/14/2003US20030153514 Anticarcinogenic agents has a saccharide having steric structure, activating natural killer T cell ability; food supplements
08/14/2003US20030153513 Preventives or remedies for obesity or fatty liver
08/14/2003US20030153510 Novel compounds inhibiting factor xa activity
08/14/2003US20030153509 Inhibiting the dipeptidylpeptidase proteolysis of Glucagon-like peptide, by administering a dipeptides consisting Pro-Pro, Ala-Pro, and (D)-Ala-(L)-Ala; treating metabolism disorders, diabetes, obesity, atherosclerosis
08/14/2003US20030153508 Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient
08/14/2003US20030153507 HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
08/14/2003US20030153504 Antiinflammatory agents selects from a group of tetrapeptides, hexapeptides, octapeptides, oligopeptides, polypeptides
08/14/2003US20030153503 Therapeutic treatment of hypoxia, anemia, and enzyme inhibitors; antihypoxic agents
08/14/2003US20030153502 A water-soluble polypeptide having hydrophobic side chains, for use as bactericides treating infections, detoxification of endotoxin, cell antiproliferative agents, antagonist of tumor necrosis factor
08/14/2003US20030153493 Combination cancer therapy
08/14/2003US20030153492 Novel glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
08/14/2003US20030153490 Insulin conjugates and methods of use thereof
08/14/2003US20030153488 Method for reducing inflammation and inducing an analgesic effect and compounds thereof
08/14/2003US20030153086 Such as iron hydroxide and sodium iron gluconate in glucose; blood disorders; storage stability
08/14/2003US20030153075 TGF-beta-specific covalently closed antisense molecule
08/14/2003US20030153063 Polypeptides; membrane proteins for diagonsis, prevention and treatment of cardiovascular disorders
08/14/2003US20030153016 PSCA: prostate stem cell antigen
08/14/2003US20030153002 Ribosome structure and protein synthesis inhibitors
08/14/2003US20030152973 G-protein coupled receptor org3
08/14/2003US20030152970 Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
08/14/2003US20030152968 Methods for detection of promoter polymorphism in a UGT gene promoter
08/14/2003US20030152935 Comprises hybridization probes; electrophoresis; drug screening
08/14/2003US20030152912 Multiple viral replicon culture systems
08/14/2003US20030152664 Microbiocides fatty acid mixed with feed
08/14/2003US20030152657 Using plant extracts for gastrointestinal disorders
08/14/2003US20030152654 Ginkgo biloba composition, method to prepare the same and uses thereof
08/14/2003US20030152653 Echinacea supplement and method of manufacture
08/14/2003US20030152651 Herbal composition for angina pectoris, method to prepare same and uses thereof
08/14/2003US20030152650 Pharmaceutical composition for prevention and treatment of premature ejaculation and/or hypersensitivity of sexual stimulation
08/14/2003US20030152649 Solvent extraction; Crohn's disease, inflammatory bowel disorders
08/14/2003US20030152648 Solvent extraction, distillation biomass
08/14/2003US20030152646 Central nervous system disorders; Alzheimer's and Parkinson'sdisease; administering tumor necrosis factor antagonist
08/14/2003US20030152644 Synergistic mixture of octoxyglycerin and microbiocide
08/14/2003US20030152643 Combination of an alpha-adrenergic antagonist and a nitrogen oxide donor for treating female sexual dysfunctions
08/14/2003US20030152642 Mixture of chondroitin sulfate, glucosamine and hyaluronic acid
08/14/2003US20030152638 Injectable opioid partial agonist or opioid antagonist microparticle compositions and their use in reducing consumption of abused substances
08/14/2003US20030152637 Administering by injection; glycolic acid-lactic acid copolymer; sustained release particles
08/14/2003US20030152628 Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in an immediate-release layer with levodopa ethyl ester in a controlled release core
08/14/2003US20030152627 Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
08/14/2003US20030152626 Substance P antagonist; antidepressants; central nervous system disorders; respiratory system disorders
08/14/2003US20030152624 Controlled release dosage form having improved drug release properties
08/14/2003US20030152622 Formulation of an erodible, gastric retentive oral diuretic
08/14/2003US20030152620 Tablet formulations comprising valsartan
08/14/2003US20030152617 Capsule, tablet with enteric, protective coatings; bioavailability
08/14/2003US20030152615 Enhanced drug delivery in transdermal systems
08/14/2003US20030152614 Enhanced drug delivery in transdermal systems
08/14/2003US20030152613 Steroid on carrier containing pressure sensitive adhesive
08/14/2003US20030152611 Pharmaceutical compositions for transdermal administration of anti-inflammatory agents
08/14/2003US20030152596 Mixture of elastase inhibitor and fungicide or bactericide; antiinflammatory agent
08/14/2003US20030152595 Storage stability
08/14/2003US20030152588 Antiproliferative agents; antiinflammatory agents; topical therapy
08/14/2003US20030152587 Immunomoderators; high molecular weight polysaccharides
08/14/2003US20030152582 CTL epitopes from EBV
08/14/2003US20030152574 Modulate nucleic acid gene expression
08/14/2003US20030152566 Soluble CD40L (CD154) as a prognostic marker of atherosclerotic diseases
08/14/2003US20030152557 Methods for inhibiting histone deacetylase-4
08/14/2003US20030152552 Synergistic mixture; viricides, antiproliferative agents, antiinflammatory agents; side effect reduction
08/14/2003US20030152547 Three-dimensional networks; biocompatibility
08/14/2003US20030152536 Cosmetic preparations containing waltheria indica extracts
08/14/2003US20030152531 Multifunctional particulate additive for personal care and cosmetic compositions, and the process of making the same
08/14/2003US20030152523 Prepared by spray-drying hydrophobic active agent (e.g. declomethasone dipropionate) with a small quantity of pharmaceutically acceptable hydrophilic polymer (e.g. polyvinyl alcohol); asthma
08/14/2003US20030152522 System for delivering antiadhesion composition comprising canister containing composition, valve adapted to permit flow of antiadhesion composition therethrough, pressure source; surgery
08/14/2003US20030152520 5-Substituted-2-arylpyridines
08/14/2003CA2776902A1 Salts of valsartan
08/14/2003CA2749205A1 The synthesis of naturally occurring ecteinascidins and related compounds
08/14/2003CA2737565A1 N-phenyl-2-pyrimidine-amine derivatives
08/14/2003CA2697599A1 Method of treating and preventing bone loss
08/14/2003CA2486446A1 Substituted fused pyrazolecarboxylic acid arylamides and related compounds
08/14/2003CA2483630A1 Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations
08/14/2003CA2482559A1 Processes for preparing crystalline and amorphous mupirocin calcium
08/14/2003CA2478423A1 Gamma secretase inhibitors
08/14/2003CA2476888A1 Targeted drug delivery methods
08/14/2003CA2476281A1 Pyrimidine compounds
08/14/2003CA2476275A1 Schwann cell bridge implants and phosphodiesterase inhibitors to stimulate cns nerve regeneration
08/14/2003CA2476218A1 Therapeutic compounds
08/14/2003CA2475839A1 Combination therapy for treatment of schizophrenia
08/14/2003CA2475767A1 Opioid receptor active 4-(3-hydroxyphenyl) or 4-(3-alkoxyphenyl)-1,2,4-triazole compounds
1 ... 5376 5377 5378 5379 5380 5381 5382 5383 5384 5385 5386 5387 5388 5389 5390 5391 5392 5393 5394 5395 5396 ... 7860